- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FCS Adds New In-House, Precision Oncology Capabilities
Florida Cancer Specialists & Research Institute announced the formation of additional precision oncology capabilities and resources comprised of geneticists, informatics specialists, and database technologies that will enhance patient care through comprehensive analysis of molecular data.
Fort Myers, Florida — Florida Cancer Specialists & Research Institute (FCS) recently announced the formation of additional precision oncology capabilities and resources to enhance patient care through comprehensive analysis of molecular data.
Comprised of geneticists, informatics specialists, and database technologies, the newly formed FCS Precision Oncology Informatics Team is focused on facilitating and streamlining the delivery of real-world data (RWD) and real-world evidence (RWE). The enhanced data collection provided to FCS physicians, researchers, and drug development teams seeks to enable optimized decision-making related to targeted treatment options and clinical trial matches.
“Being on the leading edge of healthcare, through investments in precision medicine, novel treatment pathways, and a steadfast commitment to delivering value-based care throughout the state, where and when our patients need us, regardless of age, gender, race, ethnicity, identify, or any social status is ingrained in our core strategy as a practice,” said Nathan H. Walcker, MBA, chief executive officer of FCS.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
